Frits van Rhee, MD
Hematology & Oncology · Little Rock, ARNPI 1972693455
Payments from drug & device makers
Across 227 payments — averaging $3475.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$215K
- AbbVie$176K
- Genentech, Inc.$98K
- Recordati_rare_diseases_inc.$48K
- Bristol Myers Squibb$46K
- GSK$32K
- plus $175K from 16 others
Across 1 payment — averaging $135.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$135
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $214,834 |
| AbbVie | 30 | $175,761 |
| Genentech, Inc. | 8 | $98,039 |
| Recordati_rare_diseases_inc. | 15 | $48,096 |
| Bristol Myers Squibb | 6 | $45,581 |
| GSK | 8 | $32,180 |
| Janssen Research & Development, LLC | 10 | $30,648 |
| EUSA Pharma (US) LLC | 31 | $27,698 |
| Amgen | 1 | $18,571 |
| Adaptive Biotechnologies Corporation | 9 | $18,080 |
| Sanofi | 6 | $15,385 |
| Johnson & Johnson | 31 | $14,741 |
| Sanofi US Services Inc. | 8 | $10,990 |
| E.r. Squibb & Sons, L.L.C. | 4 | $10,410 |
| Regeneron | 10 | $9,988 |
| Janssen Scientific Affairs, LLC | 5 | $5,705 |
| Clinigen, Inc. | 1 | $4,683 |
| Karyopharm Therapeutics Inc. | 5 | $3,750 |
| Janssen Global Services, LLC | 3 | $3,332 |
| Menarini Silicon Biosystems, Inc. | 1 | $500 |
| Epizyme, Inc. | 1 | $30 |
| Acrotech Biopharma Inc. | 1 | $14 |
How this compares
$789,016 in reported general payments places this provider in the 90th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Little Rock
- Ryan HallLittle Rock$4.1M
- Issam MakhoulLittle Rock$3.4M
- Carolina SchinkeLittle Rock$932K
- Kamal PatelLittle Rock$696K
- Rhonda GentryLittle Rock$328K
- Appalanaidu SasapuLittle Rock$313K
- Joseph BeckLittle Rock$261K
- Pooja MotwaniLittle Rock$222K
- David KupermanLittle Rock$187K
- Brad BaltzLittle Rock$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.